Efficacy and Safety of Tenapanor in Patients with Hyperphosphatemia Receiving Maintenance Hemodialysis: A Randomized Phase 3 Trial

BACKGROUND: Guidelines recommend reducing elevated serum phosphate in patients with CKD. Tenapanor, a minimally absorbed inhibitor of gastrointestinal sodium/hydrogen exchanger 3 (NHE3), reduces paracellular phosphate transport. METHODS: In this phase 3 randomized, double-blind trial, we randomly as...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:J Am Soc Nephrol
Egile Nagusiak: Block, Geoffrey A., Rosenbaum, David P., Yan, Andrew, Chertow, Glenn M.
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: American Society of Nephrology 2019
Gaiak:
Clinical Research
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC6442342/
https://ncbi.nlm.nih.gov/pubmed/30846557
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1681/ASN.2018080832
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak